The data was presented for the first time last week and suggests that when compared to other valves, DurAVR™ demonstrates the normal hemodynamic function of a healthy pre diseased valve.
“Better patient outcomes”
Chief Executive Officer Wayne Paterson said: “The data based on bench tests further replicates data seen in both animal and ongoing human studies and promises better patient outcomes in the future.
“Bringing the mean gradient down to within normal range (> 40 mm Hg to 4 mm Hg) will significantly improve patient quality of life as the DurAVR™ valve lasts longer and works better.”
The data showed the benefits of the valve
Valve replacement solution
The ADAPT® tissue platform, a next-generation technology with zero DNA and zero glutaraldehyde, is the only bioscaffold to demonstrate zero calcification after 10 years of use in complex cardiac surgery.
Its best-in-class ADAPT® tissue combined with its valve design has the potential to solve the problems associated with current aortic valve replacement options which are durability and preventing valve degradation.
Recordings of the symposium and the research note by Credit Suisse can be viewed at the following websites: